The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Predicting treatment outcomes in patients with r/r cHL with ctDNA and PET
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses using circulating tumor DNA (ctDNA) and interim positron emission tomography (PET) to predict outcomes of using the BEGEV (bendamustine, gemcitabine, vinorelbine) regimen in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). Patients with a high baseline ctDNA and positive PET scan had inferior treatment-free survival outcomes, with a vast majority of patients in this category needing additional treatment. Using ctDNA profiling and PET scans as predictors will consequently identify patients who may not be suited for the BEGEV regimen. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
